http___medlib.mef.hr_1661__1.xml
1.1 1.2 2.1 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 4.1 5.1 6.1
Ivković, Alan and Pascher, Arnulf and Hudetz, Damir and Matičić, Dražen and Jelić, Mislav and Dickinson, Sally and Loparić, Marko and Hašpl, Miroslav and Windhager, Reinhard and Pećina, Marko (2010) Articular cartilage repair by genetically modified bone marrow aspirate in sheep. Gene Therapy, 17 (6). Abstract Bone marrow presents an attractive option for the treatment of articular cartilage defects as it is readily accessible, it contains mesenchymal progenitor cells that can undergo chondrogenic differentiation and, once coagulated, it provides a natural scaffold that contains the cells within the defect. This study was performed to test whether an abbreviated ex vivo protocol using vector-laden, coagulated bone marrow aspirates for gene delivery to cartilage defects may be feasible for clinical application. Ovine autologous bone marrow was transduced with adenoviral vectors containing cDNA for green fluorescent protein or transforming growth factor (TGF)-beta1. The marrow was allowed to clot forming a gene plug and implanted into partial-thickness defects created on the medial condyle. At 6 months, the quality of articular cartilage repair was evaluated using histological, biochemical and biomechanical parameters. Assessment of repair showed that the groups treated with constructs transplantation contained more cartilage-like tissue than untreated controls. Improved cartilage repair was observed in groups treated with unmodified bone marrow plugs and Ad.TGF-beta1-transduced plugs, but the repaired tissue from TGF-treated defects showed significantly higher amounts of collagen II (P<0.001). The results confirmed that the proposed method is fairly straightforward technique for application in clinical settings. Genetically modified bone marrow clots are sufficient to facilitate articular cartilage repair of partial-thickness defects in vivo. Further studies should focus on selection of transgene combinations that promote more natural healing. Actions (login required) Downloads Downloads per month over past year
1.1 1.2 2.1 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 4.1 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 5.20 5.21 5.22 6.1
Ivković, Alan (2009) Cijeljenje oštećenja zglobne hrskavice nakon liječenja genski promijenjenim ugruškom autologne koštane moždine. PhD thesis, Sceučilište u Zagrebu. Croatian abstract Ozljede i oštećenja zglobne hrskavice vrlo su česte u ortopediji i sportskoj medicini, a svako takvo oštećenje predstavlja rizik za rani razvoj osteoartritisa, uz značajno smanjenje kvalitete života i povećanje troškova zdravstvene zaštite. Iako se trenutačno korištenim metodama liječenja oštećenja hrskavice postižu vrlo dobri klinički rezlutati u smislu smanjenja bolova i poboljšanja opsega pokreta, niti jedna metoda nije do sada uspjela u potpunosti regenerirati normalnu hijalinu hrskavicu. Upravo zbog toga, istraživanja novih mogućnosti liječenja oštećenja zglobne hrskavice predstavljaju izazov podjednako i za kliničare i za one koji se bave bazičnom znanošću. Temeljna hipoteza ovog istraživanja jest da je uporabom adenoviralnog vektora koji nosi gen za kodiranje transformirajućeg faktor rasta-B1 (TGF-B1) moguće uspješno transducirati stanice autologne koštane moždine, koje se potom u obliku ugruška implantiraju na mjesto hrskavičnog oštećenja, a novostvorena hrksavica je kvalitativno bolja od one stvorene bez uporabe genske terapije, odnosno od one stvorene samo umetanjem nepromijenjenog uguška. Ciljevi ovog istraživanja bili su dokazati translacijsku vrijednost predložene metode, analizirati učinke transdukcije autologne koštane moždine faktorom rasta TGF-B1 na obnovu hrskavičnog miljea u oštećenju, i to procjenom histoloških, biokemijskih i biomehaničkih parametara. Pored toga cilj je bio utvrditi moguće „istjecanje“ virusnog vektora u stanice sinovijalne ovojnice. Nakon pribavljenog odobrenja Etičkih povjerenstava, u istraživanju su korištene ovce (n=28) u dobi od 1 do 3 godina. Na medijalnom kondilu femura učinjeno je djelomično hrskavično oštećenje upotrebom instrumenta za mozaikplastiku, u koje je potom transplantiran ugrušak autologne koštane moždine. Ugrušak je u odgovarajućim skupinama prethodno genski promijenjen upotrebom adenoviralnog vektora, odnosno transplantiran je nepromijenjen u kontrolnoj 94 skupini. Metodom slučajnog odabira životinje su podijeljene u 4 skupine: CON (kontrolna skupina, prazno oštećenje, n=6), BMC (pozitivna kontrola, transplantiran nepromijenjen ugrušak, n=6), GFP (pozitivna kontrola, transplantiran ugrušak prethodno transduciran da proizvodi GFP, n=6), te TGF (ispitivana skupina, transplatiran ugrušak prethodno transduciran da proizvodi TGF-B1, n=10). Zdrava hrskavica iz kontralateralnog koljena svake životinje korištena je kao kontrola ispitivanim skupinama. Životinje su žrtvovane prema protokolu istraživanja nakon 6 mjeseci, a nakon žrtvovanja učinjena je histološka, biokemijska i biomehanička analiza novostvorenog tkiva. Rezultati provedenog istraživanja potvrdili su postavljenu hipotezu, te pokazali kako je primjenom predloženog ex vivo protokola za upotrebu genski promijenjenog ugruška autologne koštane moždine moguće dobiti hrskavični reparat zadovoljavajuće kvalitete, a uporaba faktora rasta TGF-B1 dodatno poboljšava kvalitetu novostvorenog tkiva. To je razvidno iz analize histoloških preparata koji pokazuju da je u svim tretiranim skupinama došlo do stvaranja reparata, osim u kontrolnoj skupini s praznim oštećenjem. Rezultati biokemijske analize pokazuju optimalan udio glikozaminoglikana i kolagena tipa II jedino u skupini tretiranoj s TGF-B1. Analiza biomehaničkih parametara IT AFM metodom otkriva kako je na mikrometarskom nivou reparat hrskavice iz TGF skupine najsličniji nativnoj hrksavice, dok je na nanometarskom nivou rezultat nešto lošiji obzirom na visoki ukupni udio kolagena i nizak udio vode. PCR analiza potvrdila je odsutstvo virusa iz svih analiziranih uzoraka sinovijalne ovojnice. Na osnovi rezultata provedenog istraživanja može se zaključiti kako je primjenom ugruška autologne koštane moždine moguće dobiti zadovoljavajuć reparat hrskavice u svim promatranim skupinama. Dodatna poboljšanja u kvaliteti reparata moguće je ostvariti adenoviralnim prijenosom gena za kodiranje TGF-B1 koji se luči unutar samog ugruška, te in situ usmjerava i regulira hondrogenezu. English abstract Articular cartilage injuries are very common in orthopaedic surgery and sports medicine, and often, with time they lead to premature osteoarthritis, and consequently a decrease in quality of life and increase in costs of health care. Although mentioned procedures produce good clinical result in terms of pain relief and improvement of joint function, none of the currently used methods results in regeneration of healthy hyaline cartilage. Due to that fact, numerous preclinical and clinical studies are trying to overcome existing problems and suggest novel, improved methods to treat cartilage defects. Central hypothesis of the proposed study suggest that is possible to use adenoviral vector carrying gene for coding TGF-B1 to transduce autologous bone marrow clot which is subsequently implanted into partial-thickness cartilage defects, and the newly formed tissue within the defect is qualitatively superior to the one formed without gene therapy. The aims of the proposed study are to: evaluate translational value of the proposed method, to analyze effects of the transduction with TGF-B1 on restoration of cartilage by evaluation histological, biochemical and biomechanical parameters. Additional aim was to determine if there is a vector “leakage” from the clot into the surrounding synovial tissue. Upon obtaining local Ethical Committee approval, 28 skeletally mature sheep (1 to 3 years old) were used in this study. The sheep were randomly assigned to one of four groups. Partialthickness chondral defect was made on the weight-bearing surface of the medial condyle with standard mosaicplasty instrument, and corresponding bone marrow clots were carefully inlaid into the defects without material fixation. In the bone marrow clot (BMC) group (n=6), the sheep were implanted with untreated autologous bone marrow clot that was aspirated from iliac crest of respected animal. In the bone marrow transduced with Ad.GFP (GFP) group (n=6), the sheep were implanted with autologous bone marrow clots 96 genetically modified to over express green fluorescent protein (GFP). In the bone marrow transduced with Ad.TGF-B1 (TGF) group (n=10), the sheep were implanted with autologous bone marrow clots genetically modified to over express transforming growth factor-B1. Six untreated sheep served as a control (defect without implant). Undamaged control articular cartilage also was taken from the medial condyle of the contralateral knee joint. All sheep were euthanatized 6 months after surgery, and histological, biochemical and biomechanical parameters of the newly formed tissue from the defect were analyzed. The results confirmed the central hypothesis, as they showed that it is possible to use abbreviated ex vivo protocol for genetical modification of autologous bone marrow clots to produce repair tissue within the defect, and the use of TGF-B1 additionally improves the quality of newly formed cartilage. Histological analysis showed that new tissue formed in all the treatment groups except in the empty controls, and the biochemical analysis showed optimal content of glycosaminoglycans and collagen type II only in TGF treated group. IT AFM revealed that, on micrometer scale of tissue organization, newly formed cartilage from TGF treated group has biomechanical properties that are the closest to the native cartilage. On nanometer scale, the results are suboptimal due to high overall collagen content and low water content. PCR analysis of the synovial lining tissue could not detect residual presence of vector in none of the experimental groups. The results suggest that proposed method is a single-step procedure that can be easily implemented in standard clinical settings, and avoids the use of expensive in vitro production of autologous, engineered tissues. It was possible to produce cartilage tissue of satisfactory quality, and further improvements may be obtained with adenoviral transfer of TGF-B1 that is secreted within the clot, and it stimulates and regulates the chondrogenesis process in situ. Actions (login required)